Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism

Summary

To provide palopegteriparatide (TransCon PTH), an investigational parathyroid hormone (PTH) replacement therapy in an expanded access setting for adult patients with hypoparathyroidism who have previously received PTH-treatment, who meet the eligibility criteria for this protocol as described below and have a clear unmet medical need that cannot be adequately treated by a commercial product or a clinical trial.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications